RU2014132706A - Нуклеиновые кислоты, специфически связывающие cgrp - Google Patents

Нуклеиновые кислоты, специфически связывающие cgrp Download PDF

Info

Publication number
RU2014132706A
RU2014132706A RU2014132706A RU2014132706A RU2014132706A RU 2014132706 A RU2014132706 A RU 2014132706A RU 2014132706 A RU2014132706 A RU 2014132706A RU 2014132706 A RU2014132706 A RU 2014132706A RU 2014132706 A RU2014132706 A RU 2014132706A
Authority
RU
Russia
Prior art keywords
nucleic acid
seq
acid molecule
molecule according
cgrp
Prior art date
Application number
RU2014132706A
Other languages
English (en)
Russian (ru)
Inventor
Зимоне ШУЛЬЦХЕН
Вернер ПУРШКЕ
Флориан Ярош
Кай ХЕЛИГ
Кристиан Мааш
Свен Клуссманн
Original Assignee
Ноксон Фарма Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/000089 external-priority patent/WO2012095303A1/en
Application filed by Ноксон Фарма Аг filed Critical Ноксон Фарма Аг
Publication of RU2014132706A publication Critical patent/RU2014132706A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2014132706A 2012-01-10 2013-01-10 Нуклеиновые кислоты, специфически связывающие cgrp RU2014132706A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12000105 2012-01-10
EP12000105.2 2012-01-10
EPPCT/EP2012/000089 2012-01-10
PCT/EP2012/000089 WO2012095303A1 (en) 2011-01-10 2012-01-10 Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same
PCT/EP2013/000055 WO2013104539A1 (en) 2012-01-10 2013-01-10 Nucleic acids specifically binding cgrp

Publications (1)

Publication Number Publication Date
RU2014132706A true RU2014132706A (ru) 2016-02-27

Family

ID=48781062

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014132706A RU2014132706A (ru) 2012-01-10 2013-01-10 Нуклеиновые кислоты, специфически связывающие cgrp

Country Status (14)

Country Link
US (1) US9163243B2 (cg-RX-API-DMAC7.html)
EP (1) EP2802659A1 (cg-RX-API-DMAC7.html)
JP (1) JP2015506174A (cg-RX-API-DMAC7.html)
KR (1) KR20140111704A (cg-RX-API-DMAC7.html)
CN (1) CN104136612A (cg-RX-API-DMAC7.html)
AU (1) AU2013209130A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014016939A2 (cg-RX-API-DMAC7.html)
CA (1) CA2860809A1 (cg-RX-API-DMAC7.html)
HK (1) HK1198370A1 (cg-RX-API-DMAC7.html)
IL (1) IL233515A0 (cg-RX-API-DMAC7.html)
MX (1) MX2014008456A (cg-RX-API-DMAC7.html)
RU (1) RU2014132706A (cg-RX-API-DMAC7.html)
SG (1) SG11201403769YA (cg-RX-API-DMAC7.html)
WO (1) WO2013104539A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2815444C2 (ru) * 2018-11-12 2024-03-15 Аптарион Биотех Аг Cxcl8-связывающие нуклеиновые кислоты

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2802660T (pt) 2012-01-10 2020-04-21 Aptarion Biotech Ag Novos ácidos nucleicos que se ligam a c5a
CN111973740A (zh) 2014-03-21 2020-11-24 泰华制药国际有限公司 针对降钙素基因相关肽的拮抗剂抗体及其使用方法
JP6584868B2 (ja) * 2015-02-25 2019-10-02 学校法人 関西大学 ゲル素材及びその製造方法
EA201890578A1 (ru) * 2015-09-24 2018-12-28 Тева Фармасьютикалз Интернэшнл Гмбх Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли
ES2607639B1 (es) 2015-09-30 2018-02-28 Urquima, S.A Sal de ácido maleico de un intermedio de silodosina
CN109952314A (zh) 2016-09-23 2019-06-28 泰瓦制药国际有限公司 治疗难治性偏头痛
JP2022512969A (ja) * 2018-11-12 2022-02-07 アプタリオン バイオテック エージー Ｃｘｃｌ８結合核酸

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
US6682886B1 (en) 1994-04-28 2004-01-27 Gilead Sciences, Inc. Bivalent binding molecules of 7 transmembrane G protein-coupled receptors
JPH10504457A (ja) 1994-08-16 1998-05-06 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド カルシトニンレセプター
EP1741780A3 (en) 1995-06-02 2007-03-28 Gilead Sciences, Inc. High affinity oligonucleotide ligands to growth factors
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
RU2180311C1 (ru) 2001-07-05 2002-03-10 Мешалкин Георгий Алексеевич Защитная пробка
DK1438321T5 (da) 2001-10-26 2011-02-21 Noxxon Pharma Ag Modificeret L-nukleinsyre
EP1306382A1 (de) 2001-10-26 2003-05-02 Noxxon Pharma AG Modifizierte L-Nukleinsäure
EP2138575B8 (en) 2002-02-20 2013-07-24 Mersana Therapeutics, Inc. Conjugates comprising a biodegradable polymer and uses therefor
EP1501929B1 (de) * 2002-05-06 2013-03-27 Noxxon Pharma AG Cgrp bindende nukleinsäuren
FI20051017A7 (fi) 2003-04-13 2005-11-28 Enzon Pharmaceutivals Inc Polymeeriset oligonukleotidiaihiolääkkeet
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
EP1713509A2 (de) 2004-02-09 2006-10-25 Noxxon Pharma AG Verfahren zur herstellung von konjugaten aus polysacchariden und polynukleotiden
AU2005232371B2 (en) 2004-03-23 2010-10-14 Complex Biosystems Gmbh Polymeric prodrug with a self-immolative linker
EP1807092B1 (en) 2004-11-05 2016-09-07 The Children's Hospital of Philadelphia Biodegradable linkers for molecular therapies
WO2006117217A2 (de) * 2005-05-04 2006-11-09 Noxxon Pharma Ag Neue verwendung von spiegelmeren
EP2063709A2 (en) 2006-09-15 2009-06-03 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
EP2061901A2 (en) 2006-10-31 2009-05-27 Noxxon Pharma AG Methods for detection of a single- or double-stranded nucleic acid molecule
EP2561079A1 (en) 2010-04-21 2013-02-27 Noxxon Pharma AG Lipid binding nucleic acids
EP2663640B1 (en) * 2011-01-10 2020-11-04 APTARION biotech AG Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2815444C2 (ru) * 2018-11-12 2024-03-15 Аптарион Биотех Аг Cxcl8-связывающие нуклеиновые кислоты

Also Published As

Publication number Publication date
EP2802659A1 (en) 2014-11-19
WO2013104539A1 (en) 2013-07-18
SG11201403769YA (en) 2014-07-30
US20150031755A1 (en) 2015-01-29
IL233515A0 (en) 2014-08-31
US9163243B2 (en) 2015-10-20
CN104136612A (zh) 2014-11-05
MX2014008456A (es) 2014-11-25
KR20140111704A (ko) 2014-09-19
HK1198370A1 (en) 2015-04-10
CA2860809A1 (en) 2013-07-18
AU2013209130A1 (en) 2014-07-10
BR112014016939A2 (pt) 2019-09-24
JP2015506174A (ja) 2015-03-02

Similar Documents

Publication Publication Date Title
RU2014132706A (ru) Нуклеиновые кислоты, специфически связывающие cgrp
RU2014132708A (ru) НОВЫЕ СВЯЗЫВАЮЩИЕ C5a НУКЛЕИНОВЫЕ КИСЛОТЫ
DE69637430T2 (de) Neue opioid peptide, selektiv für kappa rezeptor
JP2015506174A5 (cg-RX-API-DMAC7.html)
JP2013524792A5 (cg-RX-API-DMAC7.html)
Suat et al. Design of β-turn based therapeutic agents
JP2015509705A5 (cg-RX-API-DMAC7.html)
DE69212914T2 (de) Schnellsynthese und Screening von Peptidmimetika
JP2014533098A5 (cg-RX-API-DMAC7.html)
RU2010116245A (ru) НУКЛЕИНОВЫЕ КИСЛОТЫ, СВЯЗЫВАЮЩИЕ C5a
CN1826353A (zh) 新的黑皮质素受体模板、肽及其用途
JP2010202653A (ja) 抗梗塞分子
Todorov et al. Synthesis, characterization and nociceptive screening of new VV-hemorphin-5 analogues
Romero et al. Opioid peptide receptor studies. 12. Buprenorphine is a potent and selective μ/κ antagonist in the [35S]‐GTP‐γ‐S functional binding assay
Sluka et al. Reagents and methods for the solid-phase synthesis of protein-EDTA for use in affinity cleaving
Kokko et al. In vitro analysis of stable, receptor-selective neurotensin [8− 13] analogues
Harris et al. Antinociceptive activity of thiazole-containing cyclized DAMGO and Leu-(Met) enkephalin analogs
Ogawa et al. Synthesis and Structure− Activity Relationships of an Orally Available and Long-Acting Analgesic Peptide, N α-Amidino-Tyr-d-Arg-Phe-MeβAla-OH (ADAMB)
CN118221772A (zh) 一种μ-芋螺毒素结构优化的突变体及其应用
CN104877005A (zh) 非天然氨基酸修饰的内吗啡肽-1类似物及其合成和应用
EP2328925A1 (en) Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
CN101792487A (zh) 一种固相环化合成Laterocidin化合物的方法
US20080194467A1 (en) Cancer treatment methods using cadherin antagonists in combination with anticancer agents
DE4427980A1 (de) Nukleinsäuren-bindende Oligomere für Therapie und Diagnostik
CN107987126B (zh) 4位苯丙酰胺羟基化修饰的内吗啡肽类似物及其合成方法和应用

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20170403